P.A.W. Capital’s Gilead Sciences GILD Stock Holding History

P.A.W. Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-15,000	Closed	-$1.22M	–	62
2017 Q3	$1.22M	Sell	15,000 -15,000	-50%	-$1.15M	1.27%	30
2017 Q2	$2.12M	Buy	30,000 +15,000	+100%	+$998K	2.13%	11
2017 Q1	$1.02M	Buy	15,000 +1,000	+7%	+$70.3K	1.03%	37
2016 Q4	$1M	Sell	14,000 -4,000	-22%	-$297K	1.13%	32
2016 Q3	$1.42M	Sell	18,000 -2,000	-10%	-$162K	1.53%	26
2016 Q2	$1.67M	Buy	20,000 +8,000	+67%	+$710K	1.91%	21
2016 Q1	$1.1M	Hold	12,000	–	–	1.24%	32
2015 Q4	$1.21M	Buy	12,000 +1,000	+9%	+$104K	1.37%	33
2015 Q3	$1.08M	Buy	11,000 +2,500	+29%	+$278K	1.24%	37
2015 Q2	$995K	Buy	8,500 +1,500	+21%	+$164K	1%	37
2015 Q1	$687K	Sell	7,000 -500	-7%	-$50.8K	0.68%	51
2014 Q4	$707K	Sell	7,500 -6,500	-46%	-$672K	0.75%	47
2014 Q3	$1.49M	Sell	14,000 -11,000	-44%	-$1.08M	1.39%	28
2014 Q2	$2.07M	Buy	+25,000	New	+$1.95M	2.07%	17

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

P.A.W. Capital's GILD Position: Q4 2017 in Review

P.A.W. Capital sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 15,000 shares — an estimated $1.22M sold.

P.A.W. Capital first reported a position in GILD in Q2 2014 and held it in 14 quarters. The position peaked at $2.12M in Q2 2017. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

P.A.W. Capital reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
P.A.W. Capital sold 15,000 Gilead Sciences shares in Q4 2017, an estimated $1.22M.
P.A.W. Capital first reported a position in Gilead Sciences in Q2 2014 and held it in 14 quarters.
P.A.W. Capital's Gilead Sciences position peaked at $2.12M in Q2 2017.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on P.A.W. Capital's 13F filing for Q4 2017, filed 31 Jan 2018.